Tirzepatide is the dual GLP-1/GIP agonist behind Mounjaro and Zepbound — and it's outperforming semaglutide in head-to-head trial data. This guide explains why that happens, what SURMOUNT actually showed, how the protocol works, and what makes it different from the other GLP compounds.
Tirzepatide is a synthetic peptide developed by Eli Lilly that simultaneously activates two receptors: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). It was FDA approved as Mounjaro for type 2 diabetes in 2022 and as Zepbound for weight management in 2023.
It's often described as a "twincretin" — a portmanteau of twin and incretin, the class of gut hormones it mimics. The dual mechanism is the key differentiator from semaglutide, which targets only GLP-1.
Same mechanism as semaglutide: suppresses appetite via hypothalamic GLP-1 receptors, slows gastric emptying, glucose-dependent insulin secretion, reduces glucagon. This is the established, well-characterized arm of tirzepatide's activity.
GIP is released from K-cells in the duodenum after eating. Its receptors are expressed on pancreatic β-cells, adipose tissue, brain, bone, and gut. Key effects of GIP receptor activation:
The net result: more weight loss than GLP-1 alone, with comparable or slightly better GI tolerability. That's the clinical story of tirzepatide in one sentence.
The SURMOUNT program is tirzepatide's weight management trial series, equivalent to the STEP program for semaglutide.
| Trial | Dose | Duration | Outcome |
|---|---|---|---|
| SURMOUNT-1 | 5/10/15mg weekly | 72 weeks | 15%, 19.5%, 22.5% mean weight loss at 5/10/15mg |
| SURMOUNT-2 (T2D) | 10/15mg weekly | 72 weeks | 13.4%, 15.7% weight loss in T2D population |
| SURMOUNT-3 | 15mg weekly | 72 weeks | 26.6% loss — highest in program, after intensive lifestyle run-in |
| SURMOUNT-4 | Maintenance | 52 weeks | 14.8% weight regain in placebo arm confirms ongoing use requirement |
| SURPASS-6 (vs Sema) | 5/10/15mg vs Sema 1mg | 40 weeks | All tirzepatide doses superior to semaglutide 1mg |
SURMOUNT-3's 26.6% figure is eye-catching — that came after an intensive 12-week lifestyle run-in period. It's not the typical starting point for a research protocol, but it suggests the ceiling is higher than what standard trial conditions show.
Tirzepatide's titration schedule is slower than semaglutide's — 4 weeks per step rather than variable. Slower escalation is recommended given the more complex receptor pharmacology.
| Phase | Weekly Dose | Notes |
|---|---|---|
| Weeks 1–4 | 2.5mg | Initiation — not a therapeutic dose, purely tolerability |
| Weeks 5–8 | 5mg | First effective dose; meaningful appetite reduction begins |
| Weeks 9–12 | 7.5mg | Escalation phase |
| Weeks 13–16 | 10mg | SURMOUNT-1 showed strong results at this dose |
| Weeks 17–20 | 12.5mg | Optional intermediate step |
| Weeks 21+ | 15mg | Maximum research dose; SURMOUNT-1 top-line number |
Many research protocols maintain at 10mg rather than escalating to 15mg — the incremental benefit at 15mg exists but is smaller than the 5→10mg jump, and some subjects don't tolerate 15mg well.
GI effects are the primary concern, as with all GLP compounds. Tirzepatide's GI side effect rate in trials was comparable to semaglutide despite producing more weight loss — which is one of the reasons it's considered a favorable compound in the class.
Tirzepatide wins on weight loss in all head-to-head data. Semaglutide has longer safety track record and more cardiovascular outcome data (SELECT trial). For most weight management research protocols in 2024–2026, tirzepatide is the higher-efficacy option if cardiovascular outcome data isn't the primary endpoint.
See the full Semaglutide vs Tirzepatide comparison for complete data.
Third-party tested tirzepatide from vetted vendors. Use the codes below.